Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years

Contemporary Clinical Trials

Volumn 45, Issue , 2015, Pages 103-112

  He, Pei ^a   Lai, Tze Leung ^b   Su, Zheng ^c  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY   (United States)

^c LP   (United States)

Author keywords

Adaptive design; Calendar time; Early stopping; Multiple endpoints; Nonproportional hazards; Survival analysis

Indexed keywords

BAYES THEOREM; BOOTSTRAPPING; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; FOLLOW UP; GENOMICS; HUMAN; NEOPLASM; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; REVIEW; SAFETY; SIMULATION; STUDY DESIGN; TREATMENT FAILURE; BIOASSAY; COMPUTER SIMULATION; METHODOLOGY; NEOPLASMS; ORGANIZATION AND MANAGEMENT; PROCEDURES; PROFESSIONAL STANDARD; SURVIVAL ANALYSIS; TIME FACTOR;

BAYES THEOREM; CLINICAL TRIALS DATA MONITORING COMMITTEES; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84955195459     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.05.018     Document Type: Review

References (55)

1. D.R. Cox, Regression models and life-tables, J. R. Stat. Soc. Ser. B 34 (1972) 187-220.
2. D.R. Cox, Partial likelihood, Biometrika 62 (2) (1975) 269-276.
3. P.K. Andersen, R.D. Gill, Cox's regression model for counting processes: a large sample study, Ann. Stat. 10 (1982) 1100-1120.
4. J.M. Begun, W.J. Hall, W.M. Huang, J.A. Wellner, Information and asymptotic efficiency in parametric-nonparametric models, Ann. Stat. 11 (1983) 432-452.
5. P.K. Andersen, Ø. Borgan, R.D. Gill, N. Keiding, Statistical Models Based on Counting Processes, Springer, New York, 1993.
6. J.P. Klein, M.L. Moeschberger, Survival Analysis: Techniques for Censored and Truncated Data, Springer, New York, 2003.
7. Beta-Blocker Heart Attack Trial Research Group, A randomized trial of propranolol in patients with acute myocardial infarction: 1. mortality results, J. Am. Med. Assoc. 247 (12) (1982) 1707-1714.
8. Beta-Blocker Heart Attack Trial Research Group, Beta-blocker heart attack trial: design, methods, and baseline results, Contemp. Clin. Trials 5 (4) (1984) 382-437.
9. M. Gu, T.L. Lai, Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses, Contemp. Clin. Trials 20 (1999) 423-438.
10. K.K.G. Lan, D.L. Demets, Group sequential procedures: calendar versus information time, Stat. Med. 8 (1989) 1191-1198.
11. C.S. Chuang, T.L. Lai, Hybrid resampling methods for confidence intervals (with discussion and rejoinder), Stat. Sin. 10 (2000) 1-50.
12. T.L. Lai, W. Li, Confidence intervals in group sequential trials with random group sizes and applications to survival analysis, Biometrika 93 (2006) 641-654.
13. T.Z. Lai, M.C. Shih, Z. Su, Tests and confidence intervals for secondary endpoints in sequential clinical trials, Biometrika 96 (4) (2009) 903-915.
14. M. Gu, T.L. Lai, Weak convergence of time-sequential censored rank statistics with applications to sequential testing in clinical trials, Ann. Stat. 19 (3) (1991) 1403-1433.
15. M. Gu, T.L. Lai, Repeated significance testing with censored rank statistics in interim analysis of clinical trials, Stat. Sin. 8 (2) (1998) 411-428.
16. S.G. Self, An adaptive weighted logrank test with application to cancer prevention and screening trials, Biometrics 47 (1991) 975-986.
17. D.P. Harrington, T.R. Fleming, A class of rank test procedures for censored survival data, Biometrika 69 (3) (1982) 553-566.
18. R. Peto, J. Peto, Asymptotically efficient rank invariant test procedures, J. R. Stat. Soc. Ser. A 135 (2) (1972) 185-207.
19. R.L. Prentice, Linear rank tests with right censored data, Biometrika 65 (1) (1978) 167-179.
20. E. Slud, L.J. Wei, Two-sample repeated significance tests based on the modified Wilcoxon statistic, J. Am. Stat. Assoc. 77 (380) (1982) 862-868.
21. P. Armitage, C.K. McPherson, B.C. Rowe, Repeated significance tests on accumulating data, J. R. Stat. Soc. Ser. A 132 (1969) 235-244.
22. K.K.G. Lan, D.L. Demets, Discrete sequential boundaries for clinical trials, Biometrika 70 (3) (1983) 659-663.
23. D.O. Scharfstein, A.A. Tsiatis, The use of simulation and bootstrap in informationbased group sequential studies, Stat. Med. 17 (1) (1998) 75-87.
24. D.O. Scharfstein, A.A. Tsiatis, J.M. Robins, Semiparametric efficiency and its implication on the design and analysis of group-sequential studies, J. Am. Stat. Assoc. 92 (440) (1997) 1342-1350.
25. J. Haybittle, Repeated assessment of results in clinical trials of cancer treatment, Br. J. Radiol. 44 (526) (1971) 793-797.
26. R. Peto, M. Pike, P. Armitage, N. Breslow, D. Cox, S. Howard, N. Mantel, K. McPherson, J. Peto, P. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient 1. Introduction and design, Br. J. Cancer 34 (6) (1976) 585-612.
27. T.L. Lai, M.C. Shih, Power, sample size and adaptation considerations in the design of group sequential clinical trials, Biometrika 91 (3) (2004) 507-528.
28. D. Siegmund, Estimation following sequential tests, Biometrika 65 (1978) 341-349.
29. K.K.G. Lan, R. Simon, M. Halperin, Stochastically curtailed tests in long-term clinical trials, Commun. Stat. C Seq. Anal. 1 (3) (1982) 207-219.
30. D.Y. Lin, Q. Yao, Z. Ying, A general theory on stochastic curtailment for censored survival data, J. Am. Stat. Assoc. 94 (1999) 510-521.
31. D.J. Spiegelhalter, L.S. Freedman, D.R. Blackburn, Monitoring clinical trials: conditional or predictive power? Contemp. Clin. Trials 7 (1986) 8-17.
32. J.G. Ibrahim, M.-H. Chen, D. Sinha, Bayesian Survival Analysis, Springer, New York, 2001.
33. H. Ishwaran, L. James, Computational methods for multiplicative intensity models using weighted gamma processes: proportional hazards, marked point processes, and panel count data, J. Am. Stat. Assoc. 99 (2004) 175-190.
34. B.P. Hobbs, B.P. Carlin, Practical Bayesian design and analysis for drug and device trials, J. Biopharm. Stat. 18 (2008) 54-80.
35. S.M. Berry, B.P. Carlin, J.J. Lee, P. Müller, Bayesian Adaptive Methods for Clinical Trials, Chapman & Hall/CRC, Boca Ration FL, 2011.
36. D.A. Berry, Bayesian clinical trials, Nat. Rev. Drug Discov. 5 (2006) 27-36.
37. T.L. Lai, P.W. Lavori, K.W. Tsang, Adaptive design of confirmatory trials: advances and challenges, Contemp. Clin. Trials 45 (2015) 93-102 (in this issue).
38. R. Simon, Optimal 2-stage designs for phase II clinical trials, Contemp. Clin. Trials 10 (1) (1989) 1-10.
39. A.J. Vickers, V. Ballen, H.I. Scher, Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing, Clin. Cancer Res. 13 (3) (2007) 972-976.
40. L. Rubinstein, J. Crowley, P. Ivy, M. LeBlanc, D. Sargent, Randomized phase II designs, Clin. Cancer Res. 15 (2009) 1883-1890.
41. L.Y.T. Inoue, D.A. Berry, P.F. Thall, Seamlessly expanding a randomized Phase II trial to Phase III, Biometrics 58 (2002) 823-831.
42. X. Huang, J. Ning, Y. Li, E. Estey, J.P. Issa, D.A. Berry, Using short-term response information to facilitate adaptive randomization for survival clinical trials, Stat. Med. 28 (12) (2009) 1680-1689.
43. T.L. Lai, P.W. Lavori, M.C. Shih, Sequential design of phase II-III cancer trials, Stat. Med. 31 (18) (2012) 1944-1960.
44. P. He, T.L. Lai, O.Y.-W. Liao, Futility stopping in clinical trials, Stat. Interface 5 (2012) 415-423.
45. V. Susarla, J. Van Ryzin, Nonparametric Bayesian estimation of survival curves from incomplete observations, J. Am. Stat. Assoc. 71 (1976) 897-902.
46. R.E. Tarone, On the distribution of the maximum of the logrank statistic and the modified Wilcoxon statistic, Biometrics 37 (1981) 79-85.
47. J.L. Gastwirth, The use of maximin efficiency robust tests in combining contingency tables and survival analysis, JASA 80 (1985) 380-384.
48. T.R. Fleming, D.P. Harrington, M. O'sullivan, Supremum versions of the log-rank and generalized Wilcoxon statistics, JASA 82 (1987) 312-320.
49. J. Ganju, X. Yu, G. Ma, Robust inference from multiple test statistics via permutations: a better alternative to the single test statistic approach for randomized trials, Pharm. Stat. 12 (2013) 282-290.
50. F. Bretz, H. Schmidli, F. König, A. Racine, W. Maurer, Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts, Biom. J. 4 (2006) 623-634.
51. W. Brannath, E. Zuber, M. Branson, F. Bretz, P. Gallo, M. Posch, A. Racine-Poon, Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology, Stat. Med. 28 (2009) 1445-1463.
52. P. Bauer, Multistage testing with adaptive designs (with discussion), Biom. Inform. Med. Biol. 20 (1989) 130-148.
53. P. Bauer, K. Köhne, Evaluation of experiments with adaptive interim analyses, Biometrics 50 (1994) 1029-1041.
54. M. Jenkins, A. Stone, C. Jennison, An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints, Pharm. Stat. 10 (2011) 347-356.
55. T.L. Lai, P.W. Lavori, O.Y. Liao, Adaptive choice of patient subgroup for comparing two treatments, Contemp. Clin. Trials 39 (2014) 191-200.